Department of Ophthalmology, University of South Florida College of Medicine, Tampa, Florida, USA.
Ophthalmic Plast Reconstr Surg. 2011 May-Jun;27(3):190-4. doi: 10.1097/IOP.0b013e318201d344.
To evaluate the treatment of orbital infantile hemangiomas with systemic (oral) propranolol.
This study was a retrospective observational case series of 5 infants who were diagnosed with orbital infantile hemangiomas between March and July of 2009.
The average age at presentation was 3.1 months (3 weeks to 9 months). The patients received oral propranolol, with dosage varying among study centers. The patients were treated for an average of 7.1 months. Treatment of 5 infantile hemangioma patients with oral propranolol produced a significant reduction in the size of the hemangioma in 4 (80%) of the patients and a minimal improvement in one patient. No patient had significant adverse events during the treatment period.
Oral propranolol may be an effective treatment for orbital infantile hemangiomas.
评估系统（口服）普萘洛尔治疗眼眶婴儿血管瘤的效果。
本研究为回顾性观察性病例系列研究，纳入 2009 年 3 月至 7 月期间诊断为眼眶婴儿血管瘤的 5 例婴儿。
平均就诊年龄为 3.1 个月（3 周到 9 个月）。患者接受口服普萘洛尔治疗，各研究中心剂量不同。患者平均治疗 7.1 个月。5 例婴儿血管瘤患者接受口服普萘洛尔治疗后，4 例（80%）患者的血管瘤大小明显缩小，1 例患者有轻微改善。治疗期间无患者发生明显不良反应。
口服普萘洛尔可能是治疗眼眶婴儿血管瘤的有效方法。
